References
- Opioid overdose: prescription opioids [Internet]. Atlanta (GA): CDC; 2017 [cited 2018 Jan 26]. Available from: https://www.cdc.gov/drugoverdose/opioids/prescribed.html
- Misuse of prescription drugs [Internet]. Bethesda (MD): NIDA; 2018 [cited 2018 Jul 22]. Available from: https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/2609-misuse-of-prescription-drugs.pdf
- Vital Signs. Opioid painkiller prescribing [Internet]. Atlanta (GA): CDC; 2014 [cited 2018 Jul 22]. Available from: https://www.cdc.gov/vitalsigns/opioid-prescribing/
- What is the U.S. Opioid epidemic? [Internet]. Washington (DC): HHS; 2018 [cited 2018 Oct 10]. Available from: https://www.hhs.gov/opioids/about-the-epidemic/index.html
- Prescription opioid data [Internet]. Atlanta (GA): CDC; 2017 [cited 2018 Oct 10]. Available from: https://www.cdc.gov/drugoverdose/data/prescribing.html
- Abuse of prescription (Rx) drugs affects young adults most [Internet]. Bethesda (MD): NIH/NIDA; 2016 [cited 2018 Jul 22]. Available from: https://www.drugabuse.gov/related-topics/trends-statistics/infographics/abuse-prescription-rx-drugs-affects-young-adults-most
- Opioid overdose: prescription opioid overdose data [Internet]. Atlanta (GA): CDC; 2017 [cited 2018 Jan 26]. Available from: https://www.cdc.gov/drugoverdose/data/overdose.html
- The opioid epidemic by the numbers [Internet]. Washington (DC): HHS; 2018 [cited 2018 Oct 10]. Available from: https://www.hhs.gov/opioids/sites/default/files/2018-01/opioids-infographic.pdf
- Goodman B. Obama seeks to expand opioid addiction treatment [Internet]. New York (NY): Medscape, LLC; 2016 [cited 2018 Jan 26]. Available from: https://www.medscape.com/viewarticle/861170
- Trends & statistics [Internet]. Bethesda (MD): NIH/NIDA; 2017 [cited 2018 Jul 22]. Available from: https://www.drugabuse.gov/related-topics/trends-statistics'supplemental-references-for-economic-costs
- Hale ME, Moe D, Bond M, et al. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Pain Manag. 2016;6(5):497–508.
- Brugal M, Barrio G, Fuente L, et al. Factors associated with non-fatal heroin overdose: assessing the effect of frequency and route of heroin administration. Addiction. 2002;97(3):319–327.
- Novak S, Kral A. Comparing injection and non-injection routes of administration for heroin, methamphetamine, and cocaine uses in the United States. J Addict Dis. 2011;30(3):248–257.
- Onyeka I, Basnet S, Beynon C, et al. Association between routes of drug administration and all-cause mortality among drug users. J Subst Use. 2016;21(6):559–565.
- Glyceryl Behenate 3820–67–5. In: Lewis RJ, editor. Sax’s Dangerous Properties of Industrial Materials. Hoboken (NJ): John Wiley & Sons, Inc.; 2012.
- Carnauba Wax 8015‐86‐9. In: Lewis RJ, editor. Sax’s dangerous properties of industrial materials. Hoboken (NJ): John Wiley & Sons, Inc.; 2012. doi:10.1002/0471701343.sdp30856
- Myristic Acid 544‐63‐8. In: Lewis RJ, editor. Sax’s dangerous properties of industrial materials. Hoboken (NJ): John Wiley & Sons, Inc; 2012. doi:10.1002/0471701343.sdp43863
- Abuse-deterrent opioids — evaluation and labeling guidance for industry [Internet]. Silver Spring (MD): FDA/CDER; 2015 [cited 2018 Jan 26]. Available from: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm334743.pdf
- General principles for evaluating the abuse deterrence of generic solid oral opioid drug products guidance for industry [Internet]. Silver Spring (MD): FDA/CDER; 2017 [cited 2018 Jan 26]. Available from: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm492172.pdf
- Critical update: generic abuse deterrent opioids and the final FDA guidance [Internet]. Horsham (PA): DRUGSCAN; 2018. [cited 2018 Jul 20]. Available from: http://drugscan.com/Contents/Resources/CATonewebinars.aspx
- Evaluating the impact of abuse deterrent formulations: methodological challenges in postmarketing data. RADARS annual meeting; May 12; [Internet]. Denver (CO): RADARS; 2017 [cited 2018 Jul 20]. Available from: https://www.radars.org/system/events/RADARS%20System%202017%20Annual%20Meeting_Staffa.pdf.tmp
- Matthews F, Boehm G, Tang L, et al., inventors; Alpharma Pharmaceuticals LLC., assignee. Pharmaceutical composition. patent US 7,682,633. 2010 Mar 23.
- Katz N, Sun S, Johnson F, et al. ALO-01 (Morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. J Pain. 2010;11(4):303–311.
- Johnson F, Ciric S, Boudriau S, et al. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions. Am J Ther. 2011;18(1):2–8.
- Katz N, Hale M, Morris D, et al. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgrad Med. 2010;122(4):112–128.
- Stauffer J, Setnik B, Sokolowska M, et al. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users. A randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig. 2009;29(12):777–790.
- EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended-release capsules, for oral use, CII package insert [Internet]. New York (NY): Pfizer Inc.; 2016 [cited 2017 Jun 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022321s022lbl.pdf
- Setnik B, Goli V, Levy-Cooperman N, et al. Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. Pain Res Manag. 2013;18(4):e55–e62.
- Webster L, Johnson F, Stauffer J, et al. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Drugs R D. 2011;11(3):259–275.
- Application number: 22-321 summary review [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2008 [cited 2017 Dec 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022321s000SumR.pdf
- Badalamenti V, Buckley J, Smith E. Safety of Embeda® (Morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first year. J Opioid Manag. 2012;8(2):115–125.
- West R, Guevara M, Mikel C. Detection of naltrexone and naltrexol in patients prescribed Embeda®. J Opioid Manag. 2017;13(3):139–140.
- Ruan X, Chen T, Gudin J, et al. Acute opioid withdrawal precipitated by ingestion of crushed embeda (Morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J Opioid Manag. 2010;6(4):300–303.
- Jang D, Rohe J, Hoffman R. Severe opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda). Ann Emerg Med. 2010;55(3):303–304.
- Caruso F, Kao H, inventors; Purdue Pharma L.P., assignee. Abuse-resistant controlled-release opioid dosage form. patent US 9,511,066. 2016 Dec 6.
- Application number: 205777Orig1s000 medical review(s) [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2014 [cited 2017 Sep 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000MedR.pdf
- Application number: 205777Orig1s000 clinical pharmacology and biopharmaceutics review(s) [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2014 [cited 2017 Jul 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000ClinPharmR.pdf
- Mastropietro D, Omidian H. Abuse-deterrent formulations: part 2: commercial products and proprietary technologies. Expert Opin Pharmacother. 2015;16(3):305–323.
- FDA briefing document joint meeting of anesthetic and analgesic drug products advisory committee and drug safety and risk management advisory committee [Internet]. Silver Spring (MD): FDA; 2016 [cited 2018 Jan 29]. Available from: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM505122.pdf
- Setnik B, Bass A, Bramson C, et al. Abuse potential study of ALO-02 (Extended-release oxycodone surrounding sequestered naltrexone) compared with immediate-release oxycodone administered orally to nondependent recreational opioid users. Pain Med. 2017;18(6):1077–1088.
- Setnik B, Bramson C, Bass A, et al. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): a randomized, controlled abuse-potential study in nondependent recreational opioid users. J Clin Pharmacol. 2015;55(12):1351–1361.
- Backonja M, Webster L, Setnik B, et al. Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users. Am J Drug Alcohol Abuse. 2016;42(5):539–549.
- Malhotra B, Matschke K, Wang Q, et al. Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02). Clin Drug Invest. 2015;35(4):267–274.
- Application number: 22-272 medical review(s) [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2009 [cited 2018 Jan 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022272s000MedR.pdf
- McKenna W, Mannion R, O’Donnell E, et al., inventors; Purdue Pharma LP, Purdue Pharmaceuticals LP, assignee. Tamper resistant dosage forms. patent US 9,770,416. 2017 Sep 26.
- Application number: 22-272 clinical pharmacology and biopharmaceutics review(s) [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2009 [cited 2018 Jan 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022272s000ClinPharmR.pdf
- Harris S, Perrino P, Smith I, et al. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse‐deterrent controlled‐release tablets in recreational opioid users. J Clin Pharmacol. 2014;54(4):468–477.
- Coplan P, Chilcoat H, Butler S, et al. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. Clin Pharmacol Ther. 2016;100(3):275–286.
- Sessler N, Downing J, Kale H, et al. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiol Drug Saf. 2014;23(12):1238–1246.
- Butler S, Cassidy T, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14(4):351–358.
- Coplan P, Kale H, Sandstrom L, et al. Changes in oxycodone and heroin exposures in the national poison data system after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013;22(12):1274–1282.
- Cicero T, Ellis M. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States-lessons learned from OxyContin. JAMA Psychiatry. 2015;72(5):424–429.
- Severtson S, Ellis M, Kurtz S, et al. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug Alcohol Depend. 2016;168:219–229.
- Hwang C, Chang H, Alexander G. Impact of abuse-deterrent OxyContin on prescription opioid utilization. Pharmacoepidemiol Drug Saf. 2015;24(2):197–204.
- Severtson S, Bartelson B, Davis J, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013;14(10):1122–1130.
- Schaffer A, Buckley N, Degenhardt L, et al. Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia. Cmaj. 2018;190(12):E355–E362.
- Degenhardt L, Bruno R, Ali R, et al. The introduction of a potentially abuse deterrent oxycodone formulation: early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. Drug Alcohol Depend. 2015;151:56–67.
- Jauncey M, Livingston M, Salmon A, et al. The impact of OxyContin reformulation at the Sydney medically supervised injecting centre: pros and cons. Int J Drug Policy. 2018;53:17–22.
- Nataatmadja M, Divi D. Relapsing thrombotic microangiopathy and intravenous sustained-release oxycodone. Clin Kidney J. 2016;9(4):580–582.
- Robson K, Clucas D, Filshie R, et al. Thrombotic microangiopathy associated with intravenous injection of extended-release oxycodone. BMJ Case Rep. 2017 [cited 2018 Jan 22];1–3. DOI:10.1136/bcr-2017-220977
- Tate C, Mollee P. Intravenous oxycontin-associated thrombotic microangiopathy treated successfully without plasma exchange. Med J Aust. 2015;202(6):330–332.
- Vosburg S, Haynes C, Besharat A, et al. Changes in drug use patterns reported on the web after the introduction of ADF Oxycontin: findings from the researched abuse, diversion, and addiction-related surveillance (RADARS) system web monitoring program. Pharmacoepidemiol Drug Saf. 2017;26:1044–1052.
- OXYCONTIN® (oxycodone hydrochloride) extended-release tablets, for oral use, CII package insert [Internet]. Stamford (CT): Purdue Pharma L.P.; 2016 [cited 2017 Nov 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022272s034lbl.pdf
- Application number: 206627Orig1s000 summary review [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2014 [cited 2017 Nov 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000SumR.pdf
- Harris S, Cipriano A, Colucci S, et al. Oral abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid users. Pain Med. 2017;18:1278–1291.
- HYSINGLA ER (hydrocodone bitartrate) extended-release tablets, for oral use, CII package insert [Internet]. Stamford (CT): Purdue Pharma L.P.; 2014 [cited 2017 Nov 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206627s004lbl.pdf
- Harris S, Cipriano A, Colucci S, et al. Intranasal abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid users. Pain Med. 2016;17(5):820–831.
- Long-term safety of once-daily hydrocodone bitartrate (HYD) tablets for moderate to severe chronic nonmalignant and nonneuropathic pain. Includes a 24-week extension period [Internet]. Bethesda (MD): NIH/U.S. National Library of Medicine; 2017 [cited 2017 Nov 29]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01400139?sect=X340156'evnt
- Kapil R, Cipriano A, Wen W, et al. Pharmacokinetic profile and sustained 24-hour analgesia of a once-daily hydrocodone bitartrate extended-release tablet with abuse-deterrent properties. Clin Ther. 2016;38(2):302–314.
- Taber L, Lynch S, He E, et al. Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain. Postgrad Med. 2016;128(1):23–33.
- Application number: 208603Orig1s000 summary review [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2017 [cited 2017 Nov 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208603Orig1s000SumR.pdf
- Application number: 206544Orig1s000 summary review [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2015 [cited 2017 Dec 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206544Orig1s000SumR.pdf
- Inspirion delivery technologies receives FDA approval for MorphaBond™ (morphine sulfate) extended-release tablets CII, an opioid analgesic formulated with abuse-deterrent properties [Internet]. Valley Cottage (NY): PR Newswire; 2015 [cited 2017 Dec 2]. Available from: http://www.prnewswire.com/news-releases/inspirion-delivery-technologies-receives-fda-approval-for-morphabond-morphine-sulfate-extended-release-tablets-cii-an-opioid-analgesic-formulated-with-abuse-deterrent-properties-300153910.html
- Shah M, Difalco R, inventors; Inspirion Delivery Technologies, LLC., assignee. Abuse resistant drugs, method of use and method of making. patent US 7,955,619. 2011 Jun 7.
- Application number: 206544Orig1s000 clinical pharmacology and biopharmaceutics review(s) [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2015 [cited 2017 Dec 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206544Orig1s000ClinPharmR.pdf
- Webster L, Pantaleon C, Shah M, et al. A randomized, double-blind, double-dummy, placebo-controlled, intranasal drug liking study on a novel abuse-deterrent formulation of morphine—morphine ARER. Pain Med. 2017;18:1303–1313.
- MORPHABOND ER™ (morphine sulfate) extended-release tablets, for oral use CII Package Insert [Internet]. Basking Ridge (NJ): Inspirion Delivery Sciences, LLC; 2016 [cited 2017 Dec 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206544s002s005lbl.pdf
- Application number: 206544Orig1s000 pharmacology review(s) [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2015 [cited 2017 Dec 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206544Orig1s000PharmR.pdf
- Tygesen P, Lindhardt K, Olsen M, et al., inventors; EGALET LTD., assignee. Abuse deterrent pharmaceutical compositions for controlled release. patent US 9,549,899. 2017 Jan 24.
- Sponsor briefing document ARYMO™ ER (Morphine sulfate) extended-release tablets. Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee [Internet]. Egalet; 2016 [cited 2017 Dec 1]. Available from: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM514383.pdf
- Application number: 208603Orig1s000 chemistry review(s) [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2016 [cited 2017 Nov 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208603Orig1s000ChemR.pdf
- ARYMO™ ER (morphine sulfate) extended-release tablets, for oral use CII package insert [Internet]. Wayne (PA): Egalet US Inc.; 2017 [cited 2017 Nov 29]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208603s000lbl.pdf
- Application number: 208603Orig1s000 clinical pharmacology and biopharmaceutics review(s) [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2016 [cited 2017 Dec 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208603Orig1s000ClinPharmR.pdf
- Daiichi Sankyo, Inc. and inspirion delivery sciences LLC announce plans for commercialization of RoxyBond™ (oxycodone hydrochloride) Tablets CII in the U.S. [Internet]. Parsippany (NJ): Daiichi Sankyo, Inc; 2018 [cited 2018 Jan 29]. Available from: http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006638.html
- Kinzler E, Pantaleon C, Iverson M, et al. Oxycodone ARIR (RoxyBond™) is resistant to physical manipulation techniques commonly used by opioid abusers. Postgrad Med. 2017;129(Sup1):16.
- Webster L, Iverson M, Pantaleon C, et al. A randomized, double-blind, double-dummy, placebo-controlled, intranasal human abuse potential study of oxycodone ARIR, a novel, immediate-release, abuse-deterrent formulation. Pain Med. 2018;pny043–pny043. DOI:10.1093/pm/pny043.
- Application number: 208090Orig1s000 summary review [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2016 [cited 2017 Jul 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208090Orig1s000SumR.pdf
- Application number: 208090Orig1s000 chemistry review(s) [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2016 [cited 2017 Jul 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208090Orig1s000ChemR.pdf
- Webster L, Kopecky E, Smith M, et al. A randomized, double-blind, double-dummy study to evaluate the intranasal human abuse potential and pharmacokinetics of a novel extended-release abuse-deterrent formulation of oxycodone. Pain Med. 2016;17(6):1112–1130.
- Fleming A, Scungio T, Grima M, et al. In vitro assessment of the potential for abuse via the intravenous route of oxycodone DETERx® microspheres. J Opioid Manag. 2016;12(1):57–65.
- Gudin J, Levy-Cooperman N, Kopecky E, et al. Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med. 2015;16(11):2142–2151.
- Rariy R, Fleming A, Hirsh J, et al., inventors; Collegium Pharmaceutical Inc, assignee. Abuse-deterrent pharmaceutical compositions of opioids and other drugs. patent US 9,248,195. 2016 Feb 2.
- XTAMPZA ER (oxycodone) extended-release capsules, for oral use, CII Package Insert [Internet]. Canton (MA): Collegium Pharmaceutical Inc.; 2016 [cited 2017 Jul 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208090s003lbl.pdf
- Mayock S, Saim S, Fleming A. In vitro drug release after crushing: evaluation of Xtampza ER and other ER opioid formulations. Clin Drug Invest. 2017;37:1117–1124.
- Application number: 208090Orig1s000 medical review(s) [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2015 [cited 2017 Jul 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208090Orig1s000MedR.pdf
- Application number: 208090Orig1s000 pharmacology review(s) [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2015 [cited 2017 Jul 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208090Orig1s000PhamR.pdf
- Katz N, Kopecky E, O’Connor M, et al. A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain. Pain. 2015;156(12):2458–2467.
- McCarberg B, Kopecky E, O’Connor M, et al. An abuse-deterrent, microsphere-in-capsule formulation of extended-release Oxycodone: alternative modes of administration to facilitate pain management in patients with dysphagia. Curr Med Res Opin. 2016;32(12):1975–1982.
- Kopecky E, Fleming A, Levy-Cooperman N, et al. Oral human abuse potential of Oxycodone DETERx® (Xtampza® ER). J Clin Pharmacol. 2017;57(4):500–512.
- Application number: 208090Orig1s000 clinical pharmacology and biopharmaceutics review(s) [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2015 [cited 2017 Jul 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208090Orig1s000ClinPharmR.pdf
- Application number: 207975Orig1s000 chemistry review(s) [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2015 [cited 2017 Jul 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207975Orig1s000ChemR.pdf
- Habib W, Hamed E, Zepeda M, inventors; Cima Labs Inc., assignee. Abuse resistant drug formulation. patent US 9,216,176. 2015 Dec 22.
- Application number : 207975Orig1s000 summary review [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2017 [cited 2017 Jul 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207975Orig1s000SumR.pdf
- Arkenau-Maric E, Bartholomaus J, Kugelmann H, inventors; Grunenthal GmbH, assignee. Abuse-proof dosage form. patent US 8,192,722. 2012 Jun 1.
- Application number: 201655Orig1s000 chemistry review(s) [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2011 [cited 2018 Jan 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201655Orig1s000ChemR.pdf
- Application number: 201655Orig1s000 clinical pharmacology and biopharmaceutics review(s) [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2011 [cited 2018 Jan 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201655Orig1s000ClinPharmR.pdf
- Vosburg S, Jones J, Manubay J, et al. Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. Drug Alcohol Depend. 2012;126:206–215.
- FDA Document on Safety Issues Related to the Withdrawn Opana ER: FDA briefing document. Joint Meeting of the Drug Safety and Risk Management (DSaRM) Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) Meeting; March 13–14, 2017. Postmarketing Safety Issues Related to Reformulated Opana ER® [Internet]. Silver Spring (MD): FDA/CDER/Office of Surveillance and Epidemiology (OSE); 2017 [cited 2017 Dec 6]. Available from: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM545760.pdf
- FDA postmarket drug safety information for patients and providers. Oxymorphone (marketed as Opana ER) information [Internet]. Silver Spring (MD): FDA; 2017 [cited 2017 Dec 18]. Available from: https://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm562339.htm
- FDA briefing document. Joint Meeting of the Drug Safety and Risk Management (DSaRM) Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) Meeting; March 13–14, 2017. Postmarketing Safety Issues Related to Reformulated Opana ER® Addendum [Internet]. Silver Spring (MD): FDA/CDER/Office of Surveillance and Epidemiology (OSE); 2017 [cited 2017 Dec 19]. Available from: https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anestheticandanalgesicdrugproductsadvisorycommittee/ucm545761.pdf
- Gandhi A, Ullah S, Kotadia S, et al. Oxymorphone induced thrombotic microangiopathy mimicking atypical haemolytic uremic syndrome. J Ayub Med Coll Abbottabad. 2016;29(2):360–362.
- Ambruzs J, Serrell P, Rahim N, et al. Thrombotic microangiopathy and acute kidney injury associated with intravenous abuse of an oral extended-release formulation of oxymorphone hydrochloride: kidney biopsy findings and report of 3 cases. Am J Kidney Dis. 2014;63(6):1022–1026.
- Kotbi N, Han B, Cheng D. Opana® ER induced thrombotic thrombocytopenic purpura. Int Med Case Rep J. 2015;8:97–98.
- Hunt R, Yalamanoglu A, Tumlin J, et al. A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER. Blood. 2017;129(7):896–905.
- Application number: 20-732 and 20-733 approval letter(s) [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2002 [cited 2018 Feb 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-733_Subutex_Approv.pdf
- SUBOXONE® (buprenorphine and naloxone) sublingual film, for sublingual or buccal use CIII package insert [Internet]. North Chesterfield (VA): Indivior Inc; 2018 [cited 2018 Feb 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022410s031lbl.pdf
- Application number: 022410Orig1s000 chemistry review(s) [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2009 [cited 2018 Feb 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022410Orig1s000ChemR.pdf
- Siegel RA, Rathbone MJ. Overview of controlled release mechanisms. In: Siepmann J, Siegel RA, Rathbone MJ, editors. Fundamentals and applications of controlled release drug delivery. Boston (MA): Springer US; 2012. p. 19–43.
- Sathyan G, Sivakumar K, Thipphawong J. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. Curr Med Res Opin. 2008;24(1):297–305.
- Lussier D, Richarz U, Finco G. Use of hydromorphone, with particular reference to the OROS® formulation, in the elderly. Drugs Aging. 2010;27(4):327–335.
- Pande P, Hines J, Brogan A. Tamper-resistant properties of once-daily hydromorphone ER (OROS hydromorphone). J Pain. 2011;12(4):P58.
- Butler S, McNaughton E, Black R, et al. Evaluation of the relative abuse of an OROS(R) extended-release hydromorphone HCI product: results from three post-market surveillance studies. Clin J Pain. 2018;34(7):618–628.
- OXAYDO® (oxycodone HCl) tablets for oral use only, CII, package insert [Internet]. Wayne (PA): Egalet US Inc; 2016 [cited 2018 Jan 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202080s005s006lbl.pdf
- How could a pain treatment affect the community? [Internet]. Wayne (PA): Egalet US Inc; 2017 [cited 2018 Jan 30]. Available from: http://www.oxaydo.com/hcp/
- Maincent J, Zhang F. Recent advances in abuse-deterrent technologies for the delivery of opioids. Int J Pharm. 2016;510(1):57–72.
- Butler SF, McNaughton EC, Black RA. Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment. Pain Med. 2015;16(1):119–130.
- Dailey-Govoni T, Beaumont J, Cassidy T. PAINWeek abstract book 2017: profiling non-medical use of tapentadol products among recreational drug abusers. Postgrad Med. 2017;129(Sup 1):76–77.
- Vosburg S, Severtson S, Dart R, et al. Assessment of tapentadol API abuse liability with the researched abuse, diversion and addiction-related surveillance (RADARS) system. J Pain. 2017;19(4):439–453.
- Cone E, McGoff P, Sokolowska M, et al. PAINWeek abstract book 2017: characteristics of tapentadol extended-release formulation. Postgrad Med. 2017;129(Sup 1):44–45.
- Beaumont J, Govoni T, Cassidy T. PAINWeek abstract book 2017: abuse profile of Nucynta ER compared to extended-release opioids with and without FDA abuse-deterrent labeling. Postgrad Med. 2017;129(Sup 1):27–28.
- Application number: 200533Orig1s000 summary review [Internet]. Silver Spring (MD): FDA/CDER; 2011 [cited 2018 Jul 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200533Orig1s000SumR.pdf
- Devarakonda K, Guiliani M, Gupta V, et al., inventors; Mallinckrodt LLC, assignee. Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia. Patent US 8,658,631. 2014 Feb 25.
- Morton T, Kostenbader K, Montgomery J, et al. Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial. Postgrad Med. 2014;126(4):20–32.
- Morton T, Devarakonda K, Kostenbader K, et al. Correlation of subjective effects with systemic opioid exposure from fixed-dose combinations of oxycodone/acetaminophen in recreational users of prescription drugs. Pain Med. 2016;17(3):539–550.
- Eisenhauer T, Matchett M, Heasley R, et al. Evaluation of the tamper-resistant properties of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets. Drug Dev Ind Pharm. 2016;42(1):157–165.
- Vadivelu N, Schermer E, Kodumudi G, et al. The clinical applications of extended-release abuse-deterrent opioids. CNS Drugs. 2016;30(7):637–646.
- Pergolizzi J, Taylor R, Raffa R. The potential role of an extended-release, abuse-deterrent oxycodone/acetaminophen fixed-dose combination product for the treatment of acute pain. Adv Ther. 2015;32(6):485–495.
- Gould H, Paul D. Hydrocodone extended-release: pharmacodynamics, pharmacokinetics and behavioral pharmacology of a controversy. Pharmacol Res. 2015;91:99–103.
- Rekhi G, Sidwell R, inventors; Alkermes Pharma Ireland Limited, assignee. Abuse resistant pharmaceutical compositions. patent US 9,132,096. 2015 Sep 15.
- Farr SJ, Robinson CY, Rubino CM. Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers. Clin Pharmacol Adv Appl. 2015;7:1–9.
- Giordano J, Huang H, Kianto J, et al. In vitro assessment of the effects of alcohol on the release rate of extended-release opioid formulations (Hysingla® ER, OxyContin® and Zohydro® ER). J Pain. 2016;17(4,Supplement):S65–S66.
- Guidance for industry nonclinical studies for the safety evaluation of pharmaceutical excipients [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research; 2005 [cited 2017 Nov 20]. Available from: https://www.fda.gov/ucm/groups/fdagov-public/documents/document/ucm079250.pdf
- Guidance for industry: limiting the use of certain phthalates as excipients in CDER-regulated products [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2012 [cited 2018 Mar 1]. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM294086.pdf
- Inactive ingredient search for approved drug products [Internet]. Silver Spring (MD): FDA/Center for Drug Evaluation and Research; 2018 [cited 2018 Mar 1]. Available from: https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
- Statement from FDA commissioner Scott Gottlieb, M.D., on steps to promote development of generic versions of opioids formulated to deter abuse [Internet]. Silver Spring (MD): FDA; 2018 [cited 2018 Oct 10]. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm586117.htm